Literature DB >> 27162630

Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

Soundos Saleh1, Reiner Frey1, Corina Becker1, Sigrun Unger2, Georg Wensing1, Wolfgang Mück1.   

Abstract

Riociguat is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Some patients have difficulty swallowing tablets; therefore, 2 randomized, nonblinded, crossover studies compared the relative bioavailability of riociguat oral suspensions and immediate-release (IR) tablet and of crushed-tablet preparations versus whole IR tablet. In study 1, 30 healthy subjects received 5 single riociguat doses: 0.3 and 2.4 mg (0.15 mg/mL suspensions), 0.15 mg (0.03 mg/mL), and 1.0 mg (whole IR tablet) under fasted conditions and 2.4 mg (0.15 mg/mL) after a high-fat, high-calorie American-style breakfast. In study 2, 25 healthy men received 4 single 2.5-mg doses: whole IR tablet and crushed IR tablet suspended in applesauce and water, respectively, under fasted conditions, and whole IR tablet after a continental breakfast. In study 1, dose-normalized pharmacokinetics of riociguat oral suspensions and 1.0-mg whole IR tablet were similar in fasted conditions; 90% confidence intervals for riociguat area under the curve (AUC) to dose and mean maximum concentration (C max) to dose were within bioequivalence criteria. After food, dose-normalized AUC and C max decreased by 15% and 38%, respectively. In study 2, riociguat exposure was similar for all preparations; AUC ratios for crushed-IR-tablet preparations to whole IR tablet were within bioequivalence criteria. The C max increased by 17% for crushed IR tablet in water versus whole IR tablet. Food intake decreased C max of the whole tablet by 16%, with unaltered AUC versus fasted conditions. Riociguat bioavailability was similar between the oral suspensions and the whole IR tablet; exposure was similar between whole IR tablet and crushed-IR-tablet preparations. Minor food effects were observed. Results suggest that riociguat formulations are interchangeable.

Entities:  

Keywords:  bioequivalence; food effect; formulation; pulmonary hypertension; soluble guanylate cyclase stimulator

Year:  2016        PMID: 27162630      PMCID: PMC4860539          DOI: 10.1086/685020

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  15 in total

Review 1.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  Pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; Michael D McGoon
Journal:  Circulation       Date:  2006-09-26       Impact factor: 29.690

3.  Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.

Authors:  Reiner Frey; Wolfgang Mück; Sigrun Unger; Ulrike Artmeier-Brandt; Gerrit Weimann; Georg Wensing
Journal:  J Clin Pharmacol       Date:  2008-06-02       Impact factor: 3.126

4.  Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension.

Authors:  Marion Delcroix; Anton Vonk Noordegraaf; Elie Fadel; Irene Lang; Gérald Simonneau; Robert Naeije
Journal:  Eur Respir J       Date:  2012-08-16       Impact factor: 16.671

5.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations.

Authors:  W P Arnold; C K Mittal; S Katsuki; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

Review 6.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

7.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.

Authors:  Corina Becker; Reiner Frey; Christiane Hesse; Sigrun Unger; Michael Reber; Wolfgang Mück
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 10.  Mechanisms of disease: pulmonary arterial hypertension.

Authors:  Ralph T Schermuly; Hossein A Ghofrani; Martin R Wilkins; Friedrich Grimminger
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419

View more
  4 in total

1.  Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.

Authors:  Maulik R Patel; Kevinkumar A Kansagra; Devang P Parikh; Deven V Parmar; Hardik B Patel; Mayur M Soni; Uday S Patil; Harilal V Patel; Jaimik A Patel; Swagat S Gujarathi; Krupi V Parmar; Nuggehally R Srinivas
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.

Authors:  Reiner Frey; Corina Becker; Soundos Saleh; Sigrun Unger; Dorina van der Mey; Wolfgang Mück
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

Review 3.  Practical management of riociguat in patients with pulmonary arterial hypertension.

Authors:  Michael Halank; Kristin Tausche; Ekkehard Grünig; Ralf Ewert; Ioana R Preston
Journal:  Ther Adv Respir Dis       Date:  2019 Jan-Dec       Impact factor: 4.031

4.  Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.

Authors:  Dénes Csonka; Shirin Bruderer; Armin Schultz; Marianne Soergel; Radka Stepanova; Giancarlo Sabattini; Juan Jose Perez-Ruixo
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.